文献速递食管胃疾病与幽门螺杆菌

美国大型多样化人群中幽门螺杆菌经验性治疗的比较有效性

Comparative Effectiveness of Empiric Treatment for Helicobacter pylori in a Large, Diverse Population in the United States.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-07-14

这项回顾性队列研究在2000至2022年间于美国北加州凯撒医疗集团比较初始和补救幽门螺杆菌治疗方案的效果。在26669例初始治疗和5389例补救治疗中,PACM-14和PBMT-14的14天方案根除率最高(89.8%和88.3%),补救治疗中PBMT-14根除率最高(69.3%)。既往使用大环内酯类或甲硝唑显著降低相应方案的根除率,重复使用既往方案与根除率降低相关。

要点

  • 初始治疗中PACM-14和PBMT-14的14天方案根除率最高,分别为89.8%和88.3%。
  • 补救治疗中PBMT-14根除率最高,为69.3%。
  • 既往使用大环内酯类或甲硝唑降低相应方案根除率,应审查用药史指导选择。

核心结论

  • 在美国大型社区人群中,初始治疗时伴同疗法和铋剂四联疗法根除率最高且疗效随时间无显著下降,铋剂四联是最成功的补救方案。
  • 应审查大环内酯类或甲硝唑使用史以指导治疗选择,并应避免重复使用既往处方方案。

研究设计与样本

  • 回顾性队列研究,比较2000年至2022年间在美国北加州凯撒医疗集团(大型多样化社区医疗系统)接受初始和补救幽门螺杆菌治疗方案的 effectiveness。
  • 共纳入26669例初始治疗和5389例补救治疗。

主要发现

  • 初始治疗中PACM-14(质子泵抑制剂/阿莫西林/克拉霉素/甲硝唑)伴同疗法和PBMT-14(质子泵抑制剂/铋剂/甲硝唑/四环素)铋剂四联疗法14天方案根除率最高,分别为89.8%和88.3%,且疗效随时间无显著下降。
  • 补救治疗中所有方案根除率均显著低于初始治疗,PBMT-14根除率最高为69.3%。
  • 既往使用大环内酯类显著降低PACM-14根除率(aOR 0.68;95%CI 0.60-0.77),既往使用甲硝唑显著降低PBMT-14根除率(aOR 0.61;95%CI 0.50-0.75)。
  • 重复使用既往处方方案与根除率显著降低相关(PACM-14的aOR 0.46;95%CI 0.35-0.61;PBMT-14的aOR 0.51;95%CI 0.39-0.67)。

临床怎么用

  • 作者建议审查大环内酯类或甲硝唑使用史以指导幽门螺杆菌治疗选择。
  • 作者建议避免重复使用既往处方方案。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Treatment for Helicobacter pylori in the United States remains generally empirical due to lack of antibiotic susceptibility data. However, knowledge on comparative effectiveness of different H pylori regimens in U.S. community settings remains limited. METHODS: This retrospective cohort study compared the effectiveness of initial and salvage H pylori treatment regimens between 2000 and 2022 at Kaiser Permanente Northern California, a large, diverse, community-based healthcare system. RESULTS: Among 26,669 initial treatments and 5389 salvage treatments prescribed for H pylori-infected individuals, 14-day regimens of PACM-14 (proton pump inhibitor/amoxicillin/clarithromycin/metronidazole) (concomitant therapy) and PBMT-14 (proton pump inhibitor/bismuth/metronidazole/tetracycline) (bismuth quadruple therapy) achieved the highest eradication rates, 89.8% and 88.3%, respectively, without a substantial decline in effectiveness over time. All regimens had significantly lower eradication rates when given as salvage treatment, with PBMT-14 achieving the highest eradication rate (69.3%). Prior use of macrolides or metronidazole significantly reduced the eradication rates of clarithromycin- or metronidazole-containing regimens, respectively (adjusted odds ratio [aOR] for PACM-14, 0.68; 95% confidence interval [CI], 0.60-0.77; aOR for PBMT-14, 0.61; 95% CI, 0.50-0.75). Repeat use of previously prescribed regimens was associated with significantly lower eradication rates (aOR for PACM-14, 0.46; 95% CI, 0.35-0.61; aOR for PBMT-14, 0.51; 95% CI, 0.39-0.67). CONCLUSIONS: In a large, community-based U.S. population, concomitant and bismuth quadruple therapies had the highest eradication rates for H pylori for initial treatment without a substantial decline in efficacy over time, while bismuth quadruple was the most successful salvage regimen. History of macrolides or metronidazole use should be reviewed to inform treatment selection. Repeat use of previously prescribed regimens should be avoided.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Merchant SA, Badalov JM, Shah SC, et al. Comparative Effectiveness of Empiric Treatment for Helicobacter pylori in a Large, Diverse Population in the United States. Clin Gastroenterol Hepatol. 2025. PMID: 40669575. doi:10.1016/j.cgh.2025.06.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。